Long Noncoding RNA MALAT1 Promotes the Development of Colon Cancer by Regulating miR-101-3p/STC1 Axis [Retraction]


We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from Figures 3 and 5. Specifically,

- The image for Figure 3A, HCT116, 0h, Blank has partial duplication with the images for Figure 3A, HT29, 0h, si-NC and HT29, 48 h, Blank and has been duplicated with the image for Figure 5D, 0h, Blank.
- The image for Figure 3A, HCT116, 0h, LV-NC has partial duplication with the image for Figure 3A, HT29, 0h, Blank and has been duplicated with the image for Figure 5D, 0h, si-NC+inhibitor NC.
- The image for Figure 3A, HCT116, 0h, LV-MALAT1, has been duplicated with the image for Figure 3A, HT116, 48 h, LV-NC and Figure 5D, 0h, si-MALAT1+inhibitor NC.
- The image for Figure 3A, HCT116, 48 h, Blank has been duplicated with the image for Figure 3A, HT29, 0h, si-MALAT1 and Figure 5D, si-NC+miR-101-3p inhibitor.
- The image for Figure 3A, HT29, 0h, Blank, has been duplicated with the image for Figure 3A, HT29, 48 h, si-NC and has partial duplication with the image for Figure 5D, 48h, si-NC+inhibitor NC.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

---

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal